Spring 2025 funding cycle: Applications available until Monday, March 3.
- Call opens: Thursday, January 30, 2025
- Deadline: Monday March 3, 2025 (2:00 pm PST)
- Funding results: Available before end of May 2025
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
128 Awards
-
Does non-pyroptotic IFI16 signaling promote HIV pathogenesis by recruiting new target cells to die?
Does non-pyroptotic IFI16 signaling promote HIV pathogenesis by recruiting new target cells to die?
Abstract
Untreated HIV infection is distinguished by two major clinical hallmarks: progressive depletion of CD4 T cells, and chronic inflammation. We now know that resting “bystander” CD4 T cells in lymphoid tissue undergo a process of abortive HIV infection where incomplete reverse transcripts are formed and detected by the host DNA sensor, interferon gamma-inducible protein 16 (IFI16). This activation of IFI16 causes the assembly of an inflammasome, which cleaves caspase-1 and causes pyroptosis in the CD4 T cell.
-
Effects of Emtricitabine/tenofovir Disoproxil Fumarate Use on Kidney Health in HIV Pre-exposure Prophylaxis
Effects of Emtricitabine/tenofovir Disoproxil Fumarate Use on Kidney Health in HIV Pre-exposure Prophylaxis
Abstract
Pre-exposure prophylaxis (PrEP) with once-daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
prevents acquisition of HIV infection [1-4]. Although well tolerated, [5, 6] cases of nephrotoxicity have occurred
during TDF use, especially in HIV-infected individuals. [7-23] Such cases have resolved in most [7, 22, 24-26] but
not all [15, 19, 23, 27] persons after drug discontinuation, and may involve proximal tubular dysfunction [7-13, 16,
17, 19-22, 24, 26, 28], Fanconi syndrome, [16, 24, 25], or glomerular dysfunction.[7, 10, 11, 14, 15, 21-23, 26, 27]. -
Determining the Role of TGF-β Signaling in Maintaining HIV Latency in the Gut
Determining the Role of TGF-β Signaling in Maintaining HIV Latency in the Gut
Abstract
Gastrointestinal (GI) tract tissues harbor a large pool of cells latently infected with HIV. However, their exact identity and the mechanisms of latency are unknown. Transforming growth factor (TGF)-β has several functions in gut homeostasis, including the formation and maintenance of tissue-resident memory (TRM) CD8 T cells. Signaling by TGF-β induces expression of CD103, an αE integrin that binds to epithelial E-cadherin. CD4 TRMs also exist, but only a small proportion express CD103, and the role of TGF-β in their formation, function, and maintenance is unknown.
-
Substance Use and Depression in a National Cohort of HIV+ Latinos in HIV care
Substance Use and Depression in a National Cohort of HIV+ Latinos in HIV care
Abstract
In the United States, Latinos are disproportionately impacted by HIV and have high rates of substance use and depression. Untreated substance use and depression often co-occur and are driving poor engagement in HIV care and impeding efforts to eliminate health disparities and the reduction of new infections. This Mentored Scientist Award will support the conduct of original research in the area of substance use and depression fromthe CFAR Network of Integrated Clinical Systems (CNICS) cohort of HIV+ Latinos.
-
Influence of Antiretroviral Treatment in Acute HIV on Viral Reservoir Formation in the CNS
Influence of Antiretroviral Treatment in Acute HIV on Viral Reservoir Formation in the CNS
Abstract
In the initial days to weeks after infection with HIV, viral RNA enters the central nervous system (CNS) and is thought to form reservoirs in brain tissue that, in the long term, contribute to HIV-associated neurocognitive disorder (HAND) in up to 50% of patients. As patients are usually diagnosed with HIV well after CNS reservoirs have formed, patients with acute HIV (e.g.
-
Measuring the Uptake of Evidence Based Guidance on Antiretroviral Therapy Initiation in HIV-Tuberculosis Co-infected Persons
Measuring the Uptake of Evidence Based Guidance on Antiretroviral Therapy Initiation in HIV-Tuberculosis Co-infected Persons
Abstract
Tuberculosis (TB) is the leading cause of death among adults living with HIV in sub-Saharan Africa. Recent randomized clinical trial data has shown that earlier ART initiation (within two weeks for CD4 <50/µl and within two months for CD4 >50/µl) reduces mortality by 40 to 50%. There is a large gap, however, in the translation of this evidence into real world practice.
-
Malaria Parasitemia in HIV-infected and Uninfected Populations in Uganda
Malaria Parasitemia in HIV-infected and Uninfected Populations in Uganda
Abstract
Malaria remains one of the most formidable infectious diseases worldwide, particularly in sub-Saharan Africa, where it overlaps with the HIV epidemic. For many people in highly endemic areas, malaria parasitemia is asymptomatic, however, parasitemia provides a reservoir of parasites that drives malaria transmission.
-
Inflammatory Biomarkers in Acute and Early HIV Infection
Inflammatory Biomarkers in Acute and Early HIV Infection
Abstract
Antiretroviral (ARV) therapy has greatly reduced HIV-related mortality, but treated patients still display excess mortality compared to HIV-negative individuals. This mortality is mostly driven by "non-AIDS defining conditions" such as cardiovascular and hepatic disease as well as non-AIDS related malignancies.
-
Predictors and Optimal Diagnostics of Placental Malaria in Tororo, Uganda
Predictors and Optimal Diagnostics of Placental Malaria in Tororo, Uganda
Abstract
Malaria during pregnancy commonly leads to placental malaria, with adherence of parasite-infected erythrocytes in the placenta, and high risk of adverse maternal and fetal outcomes. Risk factors for placental malaria are not well understood. Moreover, there is an urgent need to identify optimal methods of diagnosing placental malaria.
-
Clinically Relevant Changes In Patients Treated with ARV and Antimalarial Drugs
Clinically Relevant Changes In Patients Treated with ARV and Antimalarial Drugs
Abstract